{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:18:36Z","timestamp":1780377516381,"version":"3.54.1"},"reference-count":25,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2018]]},"abstract":"<b><i>Background:<\/i><\/b> Advances in anti-lymphoma therapy prolong overall survival, making late adverse effects, like doxorubicin-related cardiotoxicity, an even more important clinical issue. The effectiveness of cardioprotective strategies with close monitoring, angiotensin-converting enzyme inhibitors and\/or \u03b2-blockers as well as liposomal doxorubicin are still unconfirmed in clinical practice. <b><i>Methods:<\/i><\/b> This study evaluated the role of a primary cardioprotection strategy in preventing cardiovascular mortality and heart failure occurrence in non-Hodgkin lymphoma (NHL) patients with a high risk of anthracycline cardiotoxicity. Thirty-five NHL patients were subjected prospectively to ramipril and\/or bisoprolol at NHL diagnosis, before implementing doxorubicin-containing regimens. Additionally, patients with a diagnosis of asymptomatic\/mild heart failure received the liposomal form of doxorubicin. The clinical outcome and frequency of all serious cardiac events were compared with the results in a historical cohort of 62 high-risk cases treated without primary cardioprotection. <b><i>Results:<\/i><\/b> NHL patients with a primary cardioprotection strategy did not experience cardiovascular deaths in contrast to the retrospective control group where cardiovascular mortality was 14.5% at 3 years (<i>p<\/i> &#x3c; 0.05). Primary cardioprotection also decreased the frequency of new cardiotoxicity-related clinical symptoms (2.8 vs. 24.1%; <i>p<\/i> &#x3c; 0.05) and prevented the occurrence of cardiac systolic dysfunction (0 vs. 8.5%, respectively; <i>p<\/i> &#x3c; 0.05). Although the study was not planned to detect any survival benefit, it demonstrated a trend towards increased response rates (complete response 82 vs. 67%; <i>p<\/i> not significant) and prolonged survival (projected 5-year overall survival 74 vs. 60%; <i>p<\/i> &#x3c; 0.05) for patients treated with primary cardioprotection. <b><i>Conclusions:<\/i><\/b> A primary personalized cardioprotection strategy decreases the number of cardiac deaths and may potentially prolong overall survival in NHL patients with increased risk of anthracycline cardiotoxicity.<\/jats:p>","DOI":"10.1159\/000492942","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T22:31:31Z","timestamp":1540852291000},"page":"238-245","source":"Crossref","is-referenced-by-count":21,"title":["Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen"],"prefix":"10.1159","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8927-4125","authenticated-orcid":false,"given":"Monika","family":"D\u0142ugosz-Danecka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja\u00a0M.","family":"Gruszka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3075-1943","authenticated-orcid":false,"given":"Sebastian","family":"Szmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Olszanecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Og\u00f3rka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Soboci\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Jaroszy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander\u00a0B.","family":"Skotnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2018,10,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg070"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1242"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.249235"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.05.013"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.654"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.08.033"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds293"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5603\/KP.2014.0126"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2008.11.023"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2014.08.009"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3109\/10611869609015970"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1444"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10201"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh393"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.004"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2017.02.073"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.5400"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2016.12.041"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2017.10.010"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-017-0938-x"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.635144"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.072"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.7830"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeu192"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013777"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/492942","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/492942","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:47:05Z","timestamp":1745426825000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000492942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,11,19]]},"published-print":{"date-parts":[[2018,11,22]]}},"URL":"https:\/\/doi.org\/10.1159\/000492942","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"value":"0009-3157","type":"print"},{"value":"1421-9794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}